Skin and Soft Tissue Infections
- Revised Publication:
- March 26, 2025
- Original Publication:
- October 2, 2014
- Declarations of Conflicts of Interest:
-
-
Pragya Dhaubhadel MD, FACP, FIDSA, declares no conflicts of interest.
- Jesse Raposa, DO, declares no conflicts of interest.
- Amit M Sharma, MD, MPH, FRCP, FAPCR, FIDSA declares no conflicts of interest
- Aditya Lal Vallath, MD, MBBS, DNB declares no conflicts of interest.
-
Pragya Dhaubhadel MD, FACP, FIDSA, declares no conflicts of interest.
- Acknowledgments:
-
Special thanks to Anucha Apisarnthanarak, MD, and Linda M. Mundy, MD, PhD for authoring the 2014 iteration of the chapter.
Abstract
In the United States, SSTIs account for 10 percent of all hospital admissions. SSTIs can be community-acquired (CA) or healthcare-associated (HA). Signs and symptoms of SSTIs range in severity from mild (e.g., localized redness and pain) to severe (e.g., abscess, necrotizing fasciitis), and some progress systemically (e.g., fever, sepsis). Staphylococcus aureus and Streptococcus pyogenes, common skin colonizers, are associated with SSTIs. Candida, a common skin commensal, can also cause SSTIs, as well as certain viruses (e.g., herpes simplex viruses [HSV], varicella zoster viruses [VZV]). Treatment depends on the severity of infection and the causative agent. Common treatments are antimicrobials, drainage, and debridement. Prevention measures, such instrument sterility, aseptic technique, hand hygiene, and wound care, play an important role in minimizing the risk of SSTIs.